Art

J-GLOBAL ID：201702252267679011   Reference number：17A1904053

Vasohibin-1 Is a Poor Prognostic Factor of Ovarian Carcinoma

バソヒビン1は,卵巣癌の不良予後因子である

Author (7)： Sano Rikiya (Department of Gynecologic Oncology, Kawasaki Medical School) ,  Kanomata Naoki (Department of Pathology 2, Kawasaki Medical School) ,  Suzuki Soichiro (Department of Gynecologic Oncology, Kawasaki Medical School) ,  Shimoya Koichiro (Department of Obstetrics and Gynecology, Kawasaki Medical School) ,  Sato Yasufumi (Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University) ,  Moriya Takuya (Department of Pathology 2, Kawasaki Medical School) ,  Shiota Mitsuru (Department of Gynecologic Oncology, Kawasaki Medical School)
Material： Tohoku Journal of Experimental Medicine  (Tohoku J Exp Med)
Volume： 243  Issue： 2  Page： 107-114(J-STAGE)  Publication year： 2017 
JST Material Number： G0649A  ISSN： 0040-8727  CODEN： TJEMAO  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *cytokine ,...
Semi thesaurus term： Ki-67

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1904053&from=J-GLOBAL&jstjournalNo=G0649A") }}

Author keywords (5)： angiogenesis ,  Ki67 ,  microvessel density ,  ovarian carcinoma ,  vasohibin-1

JST classification (1)： Tumors(=neoplasms)of female genitalia and fetus  (GS04000K)

Reference (49)：

• Affara, M., Sanders, D., Araki, H., Tamada, Y., Dunmore, B.J., Humphreys, S., Imoto, S., Savoie, C., Miyano, S., Kuhara, S., Jeffries, D., Print, C. & Charnock-Jones, D.S. (2013) Vasohibin-1 is identified as a master-regulator of endothelial cell apoptosis using gene network analysis. <i>BMC Genomics</i>, 14, 23.
• Aghajanian, C., Blank, S.V., Goff, B.A., Judson, P.L., Teneriello, M.G., Husain, A., Sovak, M.A., Yi, J. & Nycum, L.R. (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. <i>J. Clin. Oncol.</i>, 30, 2039-2045.
• Aune, G., Stunes, A.K., Tingulstad, S., Salvesen, O., Syversen, U. & Torp, S.H. (2011) The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. <i>Int. J. Clin. Exp. Pathol.</i>, 4, 444-453.
• Bookman, M.A., Brady, M.F., McGuire, W.P., Harper, P.G., Alberts, D.S., Friedlander, M., Colombo, N., Fowler, J.M., Argenta, P.A., De Geest, K., Mutch, D.G., Burger, R.A., Swart, A.M., Trimble, E.L., Accario-Winslow, C. & Roth, L.M. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. <i>J. Clin. Oncol.</i>, 27, 1419-1425.
• Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., Mannel, R.S., Homesley, H.D., Fowler, J., Greer, B.E., Boente, M., Birrer, M.J. & Liang, S.X. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. <i>N. Engl. J. Med.</i>, 365, 2473-2483.

Terms in the title (3)： バソヒビン1 ,  卵巣癌 ,  予後因子